Sirona Strategies Senior Vice President Andrew Van Ostrand was featured in Endpoints News discussing how compounded GLP-1 medications are influencing competition and pricing in the rapidly evolving weight-loss drug market.
Van Ostrand brings deep experience at the intersection of telehealth, drug compounding, and health care policy, including previously leading government affairs at Hims & Hers Health. His perspective highlights the broader policy and market implications of compounded medicines as Novo Nordisk and Eli Lilly face continued pressure around affordability and patient access.